Cargando…

Polymorphism of Drug Transporters, Rather Than Metabolizing Enzymes, Conditions the Pharmacokinetics of Rasagiline

Rasagiline is a selective and irreversible inhibitor of monoamine oxidase type B with neuroprotective effect, indicated for the management of Parkinson’s disease. The aim of this work was to evaluate the impact of seven CYP1A2 alleles and of 120 additional variants located in other CYP enzymes (e.g....

Descripción completa

Detalles Bibliográficos
Autores principales:	Zubiaur, Pablo, Matas, Miriam, Martín-Vílchez, Samuel, Soria-Chacartegui, Paula, Villapalos-García, Gonzalo, Figueiredo-Tor, Laura, Calleja, Sofía, Navares-Gómez, Marcos, de Miguel, Alejandro, Novalbos, Jesús, Mejía-Abril, Gina, Luquero-Bueno, Sergio, Román, Manuel, Ochoa, Dolores, Abad-Santos, Francisco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610285/ https://www.ncbi.nlm.nih.gov/pubmed/36297437 http://dx.doi.org/10.3390/pharmaceutics14102001

Ejemplares similares

Genetic Variation in CYP2D6 and SLC22A1 Affects Amlodipine Pharmacokinetics and Safety
por: Soria-Chacartegui, Paula, et al.
Publicado: (2023)

Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine
por: Calleja, Sofía, et al.
Publicado: (2023)

Patients’ Perceptions of Pharmacogenetic Testing and Access to Their Results: State of the Art in Spain and Systematic Review
por: Zubiaur, Pablo, et al.
Publicado: (2022)

PriME-PGx: La Princesa University Hospital Multidisciplinary Initiative for the Implementation of Pharmacogenetics
por: Zubiaur, Pablo, et al.
Publicado: (2021)

Variants in COMT, CYP3A5, CYP2B6, and ABCG2 Alter Quetiapine Pharmacokinetics
por: Zubiaur, Pablo, et al.
Publicado: (2021)

Impact of Sex and Genetic Variation in Relevant Pharmacogenes on the Pharmacokinetics and Safety of Valsartan, Olmesartan and Hydrochlorothiazide
por: Soria-Chacartegui, Paula, et al.
Publicado: (2023)

Genotype-Guided Prescription of Azathioprine Reduces the Incidence of Adverse Drug Reactions in TPMT Intermediate Metabolizers to a Similar Incidence as Normal Metabolizers
por: Casajús, Ana, et al.
Publicado: (2022)

Food Administration and Not Genetic Variants Causes Pharmacokinetic Variability of Tadalafil and Finasteride
por: Villapalos-García, Gonzalo, et al.
Publicado: (2023)

Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study
por: Soria-Chacartegui, Paula, et al.
Publicado: (2021)

Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism
por: Mejía-Abril, Gina, et al.
Publicado: (2021)

SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability
por: Zubiaur, Pablo, et al.
Publicado: (2021)

CYP2C8 *3 and *4 define CYP2C8 phenotype: An approach with the substrate cinitapride
por: Campodónico, Diana María, et al.
Publicado: (2022)

Identification of Transporter Polymorphisms Influencing Metformin Pharmacokinetics in Healthy Volunteers
por: Saiz-Rodríguez, Miriam, et al.
Publicado: (2023)

Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin
por: Villapalos-García, Gonzalo, et al.
Publicado: (2021)

Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone
por: Soria-Chacartegui, Paula, et al.
Publicado: (2021)

Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation
por: Ochoa, Dolores, et al.
Publicado: (2021)

Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates
por: Saiz-Rodríguez, Miriam, et al.
Publicado: (2020)

First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers
por: Hernández-Jiménez, Macarena, et al.
Publicado: (2022)

Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics
por: Koller, Dora, et al.
Publicado: (2020)

The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple‐dose trial
por: Koller, Dora, et al.
Publicado: (2020)

Rasagiline in treatment of Parkinson’s disease
por: Nayak, Lakshmi, et al.
Publicado: (2008)

Bioavailability of Oniria(®), a Melatonin Prolonged-Release Formulation, Versus Immediate-Release Melatonin in Healthy Volunteers
por: Román Martinez, Manuel, et al.
Publicado: (2022)

Pharmacogenetics of Donepezil and Memantine in Healthy Subjects
por: Ovejero-Benito, María C., et al.
Publicado: (2022)

The role of rasagiline in the treatment of Parkinson’s disease
por: Leegwater-Kim, Julie, et al.
Publicado: (2010)

Rasagiline Withdrawal Syndrome in Parkinson’s Disease
por: Solla, Paolo, et al.
Publicado: (2022)

Important Pharmacogenetic Information for Drugs Prescribed During the SARS‐CoV‐2 Infection (COVID‐19)
por: Zubiaur, Pablo, et al.
Publicado: (2020)

Adjunctive therapy in Parkinson’s disease: the role of rasagiline
por: Gaines, Kathryn D, et al.
Publicado: (2012)

Linezolid and Rasagiline – A culprit for serotonin syndrome
por: Hisham, Mohamed, et al.
Publicado: (2016)

Dasatinib-induced spleen contraction leads to transient lymphocytosis
por: Marcos-Jiménez, Ana, et al.
Publicado: (2022)

Engineering of Reductive Aminases for Asymmetric Synthesis of Enantiopure Rasagiline
por: Zhang, Kai, et al.
Publicado: (2021)

Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole
por: Ochoa, Dolores, et al.
Publicado: (2020)

Transmembrane protease serine 2 (TMPRSS2) rs75603675, comorbidity, and sex are the primary predictors of COVID-19 severity
por: Villapalos-García, Gonzalo, et al.
Publicado: (2022)

Correction: Transmembrane protease serine 2 (TMPRSS2) rs75603675, comorbidity and sex are the primary predictors of Covid-19 severity
por: Villapalos-García, Gonzalo, et al.
Publicado: (2022)

From a Parkinson's disease expert: Rasagiline and the Future of Therapy
por: Lakhan, Shaheen E
Publicado: (2007)

Role of rasagiline in treating Parkinson’s disease: Effect on disease progression
por: Malaty, Irene A, et al.
Publicado: (2009)

Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia
por: Matthews, Dawn C., et al.
Publicado: (2021)

Striking Neurochemical and Behavioral Differences in the Mode of Action of Selegiline and Rasagiline
por: Harsing, Laszlo G., et al.
Publicado: (2023)

Preemptive TPMT Genotyping and Adherence to Genotype-Based Therapeutic Recommendations Reduces the Healthcare Cost in Patients Receiving Azathioprine or 6-Mercaptopurine for Autoimmune Diseases
por: Valdez-Acosta, Sarahí, et al.
Publicado: (2023)

Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy
por: Lecht, Shimon, et al.
Publicado: (2007)

Rasagiline and Rapid Symptomatic Motor Effect in Parkinson’s Disease: Review of Literature
por: Pistacchi, Michele, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_spvjk8ig2b0loodc202unk4lpi